The SS Innovations team, led by Dr. Sudhir Srivastava, Chairman of the Board and CEO, successfully completed the world’s first intercontinental robotic cardiac telesurgery on July 19, 2025. This groundbreaking procedure was performed remotely from IRCAD in Strasbourg, France, to the operating room at SAIMS in Indore, India. The key players involved in this historic achievement were:
* Dr. Sudhir Srivastava, Chairman of the Board and CEO of SS Innovations
* Dr. Lalit Malik, Chief of Cardiac Surgery, Manipal Hospital, Jaipur
* Dr. Ram Krishna Shukla, Cardiologist, SAIMS, Indore
* Dr. Bipin Arya, Anesthesiologist, SAIMS, Indore
* Dr. Husam H. Balkhy, M.D., President of the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) and Professor of Surgery and Director of Robotic and Minimally Invasive Cardiac Surgery at the University of Chicago Medicine
The surgery was coordinated seamlessly, with the patient-side support team in Indore working closely with the SS Innovations and SAIMS teams. The live telesurgery was moderated by Dr. Husam H. Balkhy, who ensured a flawless and precise robotic control. Dr. Srivastava expressed his gratitude to the team involved in the historic achievement, stating that it was a testament to the advanced capabilities of the SSi Mantra 3 surgical robotic system and its revolutionary telesurgery architecture. The SSi Mantra 3 surgical robotic system is a user-friendly, modular, multi-arm system with several advanced technology features, including:
* 3 to 5 modular robotic arms
* An open-faced ergonomic surgeon command center
* A large 3D 4K monitor
* A touch panel monitor for all patient-related information display
* Virtual real-time image of the robotic patient-side arm carts
* The ability for superimposition of 3D models of diagnostic imaging
The SSi Mantra 3 has been clinically validated in India in over 100 different types of surgical procedures. **Key Statistics:**
* 35 telesurgeries have been successfully completed utilizing the SSi Mantra surgical robotic system
* 10 cardiac procedures have been performed remotely
* Over 250 cardiac procedures have been completed with the SSi Mantra system
* Over 5,000 multi-specialty surgeries have been successfully carried out with the SSi Mantra system without any device-related adverse events
The SSi Mantra 3 surgical robotic system is a testament to the company’s commitment to making robotic surgery affordable and accessible to a global population. **Regulatory Approval:**
SS Innovations is the only surgical robotic company to have received a regulatory approval from the Central Drugs Standard Control Organization (CDSCO), which is India’s equivalent of the U.S. Food and Drug Administration, for both teleproctoring and telesurgery. **About SS Innovations:**
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The company plans to expand its global presence and make its technologically advanced, user-friendly, and cost-effective surgical robotic solutions available to more people around the world. **About the SSi Mantra:**
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with several advanced technology features, including:
* 3 to 5 modular robotic arms
* An open-faced ergonomic surgeon command center
* A large 3D 4K monitor
* A touch panel monitor for all patient-related information display
* Virtual real-time image of the robotic patient-side arm carts
* The ability for superimposition of 3D models of diagnostic imaging
The SSi Mantra has been clinically validated in India in over 100 different types of surgical procedures. **Forward-Looking Statements:**
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
